Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1NCT04524195
Official study title

PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)

Study summary

This is a prospective, single center, single-arm clinical trial in 20 patients with non-small cell lung cancer (NSCLC) undergoing PD-1/PD-L1-directed therapy. This research is being done to find out if the radioactive compound called \[18F\]F-AraG is a helpful imaging agent for detecting changes in cancer's anti-tumor immune response (or activation of T-cell) levels for non-small cell lung cancer (NSCLC) patients who will receive a cancer immunotherapy regimen (immunotherapy works by encouraging the body's own immune system to attack the cancer cells).

Ask AI to explain this study
Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studied[18F]F-AraG Injection

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · PD-L1

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 17, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study sponsor

01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Phase 1
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Interventions being studied
Drug: [18F]F-AraG Injection
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Biomarkers
PD-L1→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Age 18 years or older and willing and able to provide informed consent.
  • Subjects with stage I, II, or III A NSCLC and plan to receive neoadjuvant PD-1/PD-L1 immunotherapy with an intention for curative surgery. Subjects will be receiving neoadjuvant immunotherapy through enrollment in therapeutic clinical trials
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at the time of enrollment.
  • For females of childbearing potential, negative serum pregnancy test within a 10 day period will be obtained prior to PET study.
Reasons someone may not be able to joinExclusion criteria
  • Severe impaired renal function with estimated glomerular filtration rate \<30 mL/min/1.73 m2 and/or on dialysis.
  • Pregnant female patients; breastfeeding female patients.
  • Any medical condition that in the opinion of the study investigators would constitute a safety risk to the subject.
  • Any investigational radiation exposure in the past calendar year that in combination with the radiation exposure from this study would exceed 5 rem.
  • Administered a radioisotope ≤5 physical half-lives prior to the day of PET/CT.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Johns Hopkins UniversityBaltimore, Maryland

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 17, 2024. Always confirm current availability with the study team.

View original record ↗